Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma
Michael Wang
(1)
,
Wojciech Jurczak
(2)
,
Mats Jerkeman
(3)
,
Judith Trotman
(4)
,
Pier Zinzani
(5)
,
David Belada
(6)
,
Carola Boccomini
(7)
,
Ian Flinn
(8)
,
Pratyush Giri
(5)
,
Andre Goy
(9)
,
Paul Hamlin
(10)
,
Olivier Hermine
(11)
,
José-Ángel Hernández-Rivas
(12)
,
Xiaonan Hong
(13)
,
Seok Jin Kim
(14)
,
David Lewis
(15, 16)
,
Yuko Mishima
(17)
,
Muhit Özcan
(18)
,
Guilherme Perini
(19)
,
Christopher Pocock
(20)
,
Yuqin Song
(21)
,
Stephen Spurgeon
(22)
,
John Storring
(23)
,
Jan Walewski
(2)
,
Jun Zhu
(21)
,
Rui Qin
(24)
,
Todd Henninger
(24)
,
Sanjay Deshpande
(24)
,
Angela Howes
(24)
,
Steven Le Gouill
(25)
,
Martin Dreyling
(26)
1
MD Anderson Cancer Center [Houston]
2 Maria Sklodowska-Curie National Research Institute of Oncology [Krakow, Poland]
3 Skane University Hospital [Lund]
4 The University of Sidney
5 Royal Adelaide Hospital [Adelaide Australia]
6 University of Hradec Králové
7 A.O.U - Città della Salute e della Scienza di Torino
8 Sarah Cannon Research Institute [Nashville, Tennessee]
9 John Theurer Cancer Center [Hackensack, NJ, USA]
10 MSKCC - Memorial Sloan Kettering Cancer Center
11 Hôpital Necker - Enfants Malades [AP-HP]
12 UCM - Universidad Complutense de Madrid = Complutense University of Madrid [Madrid]
13 Fudan University [Shanghai]
14 Samsung Medical Center Sungkyunkwan University School of Medicine
15 NICD - National Institute for Communicable Diseases [Johannesburg]
16 WITS - University of the Witwatersrand [Johannesburg]
17 Japanese Foundation for Cancer Research [Tokyo, Japan]
18 Ankara University School of Medicine [Turkey]
19 Hospital Israelita Albert Einstein [São Paulo, Brazil]
20 Plymouth Hospitals NHS Trust
21 Beijing University Cancer Hospital
22 OHSU - Oregon Health and Science University [Portland]
23 RI-MUHC - Research Institute of the McGill University Health Centre
24 Janssen Research & Development
25 CRCI2NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers
26 Klinikum der Universitat Munchen
2 Maria Sklodowska-Curie National Research Institute of Oncology [Krakow, Poland]
3 Skane University Hospital [Lund]
4 The University of Sidney
5 Royal Adelaide Hospital [Adelaide Australia]
6 University of Hradec Králové
7 A.O.U - Città della Salute e della Scienza di Torino
8 Sarah Cannon Research Institute [Nashville, Tennessee]
9 John Theurer Cancer Center [Hackensack, NJ, USA]
10 MSKCC - Memorial Sloan Kettering Cancer Center
11 Hôpital Necker - Enfants Malades [AP-HP]
12 UCM - Universidad Complutense de Madrid = Complutense University of Madrid [Madrid]
13 Fudan University [Shanghai]
14 Samsung Medical Center Sungkyunkwan University School of Medicine
15 NICD - National Institute for Communicable Diseases [Johannesburg]
16 WITS - University of the Witwatersrand [Johannesburg]
17 Japanese Foundation for Cancer Research [Tokyo, Japan]
18 Ankara University School of Medicine [Turkey]
19 Hospital Israelita Albert Einstein [São Paulo, Brazil]
20 Plymouth Hospitals NHS Trust
21 Beijing University Cancer Hospital
22 OHSU - Oregon Health and Science University [Portland]
23 RI-MUHC - Research Institute of the McGill University Health Centre
24 Janssen Research & Development
25 CRCI2NA - Centre de Recherche en Cancérologie et Immunologie Intégrée Nantes-Angers
26 Klinikum der Universitat Munchen
Michael Wang
- Fonction : Auteur
- PersonId : 1434391
- ORCID : 0000-0001-9748-5486
Olivier Hermine
- Fonction : Auteur
- PersonId : 1308844
- ORCID : 0000-0003-2574-3874
- IdRef : 069884927
Résumé
Ibrutinib, a Bruton's tyrosine kinase inhibitor, may have clinical benefit when administered in combination with bendamustine and rituximab and followed by rituximab maintenance therapy in older patients with untreated mantle-cell lymphoma.